Loading...
Market
How will 23andMe's stock price change by end of 2025?
2
Resolution / Starting Odds
Above 50% increase • 25%
10% to 50% increase • 25%
0% to 10% increase • 25%
Decrease • 25%
Stock market data from financial platforms like Bloomberg or Yahoo Finance
Story
23andMe Cuts 40% of Workforce, Ends Drug Development
Nov 12, 2024, 12:08 AM
23andMe, a genetic testing firm, has announced a significant restructuring program that includes reducing its workforce by approximately 40%, affecting over 200 employees, and discontinuing its drug development efforts. The company aims to streamline operations, reduce costs, and focus on its consumer genetics business. This restructuring will incur one-time costs of up to $12 million.
View original story
Similar markets
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
Below $0.50 • 25%
$0.50 - $0.99 • 25%
$1.00 - $1.49 • 25%
$1.50 and above • 25%
Stock increases by 10% or more • 25%
Stock remains within +/- 10% • 25%
Stock decreases by 10% or more • 25%
Stock remains volatile with no clear trend • 25%
Outperforms NASDAQ • 25%
Performs on par with NASDAQ • 25%
Underperforms NASDAQ • 25%
Delisted from NASDAQ • 25%
Less than $1 • 25%
$1 to $2 • 25%
$2 to $3 • 25%
More than $3 • 25%
Outperforms competitors • 25%
Matches competitors • 25%
Underperforms competitors • 25%
Significantly underperforms competitors • 25%